Compare Crispr Therapeutics AG (CRSP) vs Hewlett Packard Enterprise Co (HPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Hewlett Packard Enterprise Co — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Hewlett Packard Enterprise Co trades at $73.46 (market cap $94.25B). The key difference: Hewlett Packard Enterprise Co is far larger — about 19.3× Crispr Therapeutics AG's market cap, and Hewlett Packard Enterprise Co pays a 0.8% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Hewlett Packard Enterprise Co for 33 Days on average.
| CRSP | HPE | |
|---|---|---|
Market Cap | $4.88B | $94.25B |
Volume | 2,861,747 | 16,060,854 |
Sector | Health | Technology |
52-Week High | $74.92 | $72.12 |
52-Week Low | $44.34 | $20.01 |
Typical Hold Time | 77 Days | 33 Days |
Enterprise Value | $3.30B | $108.28B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
HPE's stock trades at $70.99, down 1.56% today but near its 52-week high, with a bullish technical outlook and strong AI-driven momentum. Recent earnings beats and a $1.2B AI server order from Vultr highlight robust demand. Valuation metrics show a P/E of 36.6 and P/S of 2.4, while cash flow trends indicate volatility with a net outflow of $9.25B in 2025 but a projected rebound in 2026.
The outlook is positive, driven by AI infrastructure growth and raised guidance, but risks include high debt levels and competitive pressures. Analyst consensus leans neutral with a $70.35 price target, suggesting cautious optimism amid near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →
